The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: rationale and methods. Int J Stroke. 2019;14:207 786. Geisler T, Poli S, Meisner C, Schreieck J, Zuern CS, N gele T, Brachmann J, Jung W, Gahn G, Schmid E, et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): rationale and study de- sign. Int J Stroke. 2017;12:985 990. doi: 10.1177/1747493016681019 787. Lopes RD, Alings M, Connolly SJ, Beresh H, Granger CB, Mazuecos JB, Boriani G, Nielsen JC, Conen D, Hohnloser SH, et al. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With CLINICAL STATEMENTS AND GUIDELINES Kleindorfer Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. Am Heart 788. Ratajczak-Tretel B, Lambert AT, Johansen H, Halvorsen B, Bjerkeli V, Russell D, Sandset EC, Ihle-Hansen H, Eriksen E, N ss H, et al. Atrial fibrillation in cryptogenic stroke and transient ischaemic attack: the Nordic Atrial Fibrillation and Stroke (NOR-FIB) study: rationale and design. Eur Stroke J. 2019;4:172 180. doi: 10.1177/2396987319837089 789. De Schryver EL, Algra A, Kappelle LJ, van Gijn J, Koudstaal PJ. Vitamin K antagonists versus antiplatelet therapy after transient isch- aemic attack or minor ischaemic stroke of presumed arterial origin. Cochrane Database Syst Rev. 2012;2012:CD001342. doi: 10.1002/ 790. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, et al; Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the preven- tion of recurrent ischemic stroke. N Engl J Med. 2001;345:1444 1451. 791. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study, 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1 13. doi: 792. 